Empagliflozin and Major Renal Outcomes in Heart Failure

Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2.8% of the patients who received empagliflozin and in 3.5% of those who received placebo. Results differed between the two trials.

Automated summary

Empagliflozin had different effects on renal outcomes in heart failure patients between two trials, with major adverse renal outcomes occurring in 2.8% of patients who received the drug and 3.5% of those who received a placebo.